CureVac is a company that makes medicine to help people not get sick from COVID-19, which is a bad virus. They are working with another big company called GSK to make two types of vaccines. A vaccine is something that helps your body learn how to fight the virus so you don't get sick. They shared some news about their vaccines and said they seem to work well, so now people are excited and want to buy more shares of CureVac, which makes the price go up. Read from source...

- The title is misleading and sensationalist, implying that the shares are rising because of some new positive data, when in fact the data is interim and not conclusive.
- The article does not provide any details on the design, methodology, or results of the Phase 2 study, only mentioning vague terms like "meaningful immune responses" and "favorable reactogenic".
- The article does not disclose any potential conflicts of interest between CureVac and GSK, or how their collaboration might affect the credibility and objectivity of the data.
- The article uses emotional language to describe the vaccine candidates, such as "modified", "bivalent", and "proprietary", without explaining what they mean or why they are important.
- The article does not compare the performance or efficacy of CureVac's vaccines with other existing or emerging COVID-19 vaccines, or provide any context on the current global situation of the pandemic.

Based on the article, here are my comprehensive investment recommendations for CureVac (CVAC) shares:

- Buy: If you believe in the potential of mRNA technology and its ability to provide effective vaccines against COVID-19 and other diseases. CVAC has a strong partnership with GSK, which can help speed up the development and distribution of their vaccine candidates. The interim data from the Phase 2 study shows promising immune responses and favorable reactogenicity, which indicates that the vaccines are safe and well-tolerated. CVAC shares have a significant upside potential if they successfully complete the clinical trials and receive regulatory approval for their vaccines.

- Sell: If you think that mRNA technology is too risky or unproven, and that there are other viable alternatives to COVID-19 vaccines. CVAC shares have experienced volatile fluctuations in the past due to the uncertainty surrounding the pandemic and the development of vaccines. You may also consider selling if you think that GSK's involvement in the partnership dilutes CVAC's value or if you are concerned about the competition from other pharmaceutical players such as Pfizer, Moderna, AstraZeneca, etc.

- Hold: If you want to maintain a balanced portfolio and diversify your exposure to different sectors and industries. CVAC shares can be a good long-term hold if you believe in the growth potential of biopharmaceuticals and mRNA technology. However, you may also want to monitor the progress of the clinical trials and the regulatory approval process for their vaccines, as well as the market sentiment and demand for COVID-19 vaccines in general. You can adjust your position accordingly based on the new information and developments.